Clinical trials
Solid Tumors Refractory to Standard Therapy clinical trials
Below are recruiting solid tumors refractory to standard therapy clinical trials, each written for real people, not researchers. We’re tracking 275 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT06895733RecruitingPhase 1/Phase 2
Pazopanib plus palbociclib for advanced solid tumors with 11q13 change
This trial tests two pills (pazopanib and palbociclib) together for people with advanced solid tumors that have a specific gene change (11q13 amplification) and have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05269316RecruitingPhase 1/Phase 2
Early-phase study of IMP9064 for advanced solid tumors
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
Hackensack, New JerseyAges 18 years+ - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07167381Recruiting
Tumor testing to find cancer treatments for Florida patients
This study tests your tumor sample to find which drugs might work best for your cancer. It is for both children and adults whose cancer has come back or not responded to treatment, and who have already tried at least one standard therapy.
Miami, FloridaAges Any age - NCT07170293RecruitingPhase 2
Testing tunlametinib for NRAS-mutant solid tumors
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07158918RecruitingPhase 1/Phase 2
Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Cleveland, OhioAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07030959RecruitingPhase 1
AUBE00 for advanced solid tumors with KRAS mutation
This trial tests an experimental drug called AUBE00 for people with solid tumors that have a KRAS mutation, after other treatments have failed. It aims to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07032077RecruitingPhase 2
HRS-7058 plus other drugs for solid tumors
This trial tests a new drug called HRS-7058 combined with other anti-tumor medicines for people with solid tumors. The goal is to see if the combination is safe and effective. It might be an option if you have advanced cancer and have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06973863RecruitingPhase 1
Study of PEP08 for advanced solid tumors with MTAP deletion
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
Wentworthville, New South WalesAges 18 years+ - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combination for advanced solid tumors
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06911008RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests an experimental drug called MTI-301 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
Jacksonville, FloridaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06874335RecruitingPhase 1
A study of BHV-1530 for advanced solid tumors
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Beverly Hills, CaliforniaAges 18 years+ - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75
Hear when a new Solid Tumors Refractory to Standard Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumors refractory to standard therapy?
- Yes. Clin2 currently lists 275 recruiting solid tumors refractory to standard therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumors refractory to standard therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumors refractory to standard therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.